Genmab — Marts 2021
-
-
-
from a patient: Finally! Insurance approved Kesimpta. Here’s how it went and how it works https://www.reddit.com/r/MultipleSclerosis/comments/mfvgch/finally_insurance_approved_kesimpta_heres_how_it/
-
Ser ud til Genman er gået i neutral på trading views TA barometer efter at have ligget i sell / strong sell et par måneder her link https://www.tradingview.com/symbols/OMXCOP-GMAB/
-
Det er helt almindelig kutyme for analytikere og kommentatorer at vurdere i medierne om hvorvidt en nyhed er kurspåvirkende eller ej
. -
Genmab-boss om sklerose-lancering: Novartis prioriterer os højt
Mens Genmabs partner Novartis med en ny EU-godkendelse til sklerosemidlet Kesimpta nu kan starte lancering i Europa, er processen allerede i fuld gang i USA – og der går det rigtig godt fortæller Genmabs adm. direktør Jan van de Winkel.
(medwatch.dk)
-
Aktier/middag: Mærsk går frem efter sats på medicin i småsurt marked:
https://www.proinvestor.com/investornyt/673637/aktier-middag-maersk-gar-frem-efter-sats-pa-medicin-i-smasurt-marked
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind


